Media Release, Melbourne

12 March 2025

COVIRIX reports successful test results on diverse influenza viruses, including seasonal flu and avian flu viruses, and RSV, building upon previous successful tests on SARS CoV-2 and multiple variants.

COVIRIX Medical, a Melbourne based pharmaceutical development company, announces today that the company has recently completed virology tests at a renowned USA university laboratory, which specializes in viral research and virology studies, affirming the antiviral activity of our antiviral drug compound against all representative human influenza A viruses (seasonal flu viruses including H5N1 Avian Flu virus) together with human respiratory syncytial virus (RSV).

Notably, these tests were performed using human airway epithelial tissues designed to closely replicate the real human respiratory tract. In this regards, it is important to note that COVIRIX Medical's patented antiviral drug is designed to be administered in Dry Powder form by oral inhalation directly to the respiratory tract. Oral Inhalation is designed to provide rapid delivery of the drug at high local concentrations to the site of respiratory virus replication: the respiratory tract. This latest virology test data support our view that our proprietary targeted dry powder inhaled approach should circumvent the potential systemic side effects of this drug class resulting from other modes of delivery. A reduction of more than 10 fold in dose, compared to systemic oral delivery is anticipated from the latest data.

The COVIRIX Medical antiviral can also be administered as a preventive against potential respiratory infections which will deliver substantially more value in disease prevention and accordingly reduce the burden on the healthcare system.

The data results from the virology tests just completed provide independent confirmation of our earlier assays conducted at Australian, USA, and Netherlands based laboratories involving the respiratory virus SARS CoV-2 and its multiple variants, confirming the broad spectrum activity.

COVIRIX Medical's compounds belong to a class of drugs that have a long, well-established history of broad spectrum antiviral activity (i.e. activity across many different species of viruses), and therefore are likely to work against known and emerging strains of respiratory viruses, including pandemic potential viruses. The class also includes several approved drugs that have been in use for many years for non-infectious diseases applications.

COVIRIX Medical's lead molecule CVX 20733, already a clinically approved drug, is a repurposed drug currently in use as an orally delivered drug for metabolic diseases which the company intends to deliver via a proprietary inhaled dose form.

The virology study just completed tested another molecule in the COVIRIX Medical portfolio, CVX 20700, which is significantly more potent than CVX 20733 and is planned to be released as a pipeline product in the future subject to successful appropriate clinical trials.

At a time when the world is immersed in an avian flu pandemic which has already infected birds, poultry, mammals and humans in all continents of the world, the successful virology test results just received by COVIRIX Medical are of significant importance to the company but they also offer to the global healthcare system a credible and valuable antiviral treatment solution when it may well be critically needed in the very near future.

Armed with these successful test results, COVIRIX Medical will be seeking partnerships with renowned medical research institutes and major pharmaceutical companies to fast track the commercialization of its patented antiviral portfolio.

Many lessons learned from the recent Covid-19 Pandemic, including that of the subsequent problem of Covid vaccine hesitancy, will likely serve to support the speedier introduction of COVIRIX Medical's antiviral treatment solution against respiratory diseases.

For enquiry, please email to Contact@covirix.com or refer to Home (covirix.com)